This can only be done if Illumina acquires GRAIL now.
#LUMINA STOCK FULL#
Illumina feels there is a moral obligation to have the deal decided by a thoughtful and full review by the EU regulators and the US courts. Cancers responsible for nearly 71% of cancer deaths have no recommended early detection screening, and most cancers are detected when chances of survival are lower. Cancer kills around 10 million people annually worldwide and 600,000 people in the US alone. The reasons to reunite the two companies are compelling: Illumina is committed to working through the ongoing FTC administrative process, and as always, will abide by whatever outcome is ultimately reached in the US courts. There is no legal impediment to acquiring GRAIL in the US. By holding GRAIL separate while proceedings are ongoing, Illumina is positioned to abide by whatever final decision is reached in these legal processes. The General Court of the European Union will hear Illumina's jurisdictional challenge later this year. GRAIL has no business in the EU, and the company believes that the European Commission does not have jurisdiction to review the merger as the EU merger thresholds are not met, nor are they met in any EU member state. Regulators in the EU are reviewing the transaction, but a decision is projected after the deal expires.
Illumina's acquisition of GRAIL will accelerate access and adoption of this life-saving test worldwide. GRAIL's Galleri blood test detects 50 different cancers before they are symptomatic.
Illumina, the global leader in DNA sequencing, first announced its intention to acquire GRAIL nearly a year ago, reuniting Illumina with GRAIL four years after it was spun off.
0 kommentar(er)
